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Background: Expression and activity of the fibroblast growth factor (FGF) 21 hormone-like protein are associated
with development of several metabolic disorders. This study was designed to investigate whether serum FGF21
level was also associated with the metabolic syndrome-related cardiovascular disease, atherosclerosis, and its clinical
features in a Chinese cohort.
Methods: Two-hundred-and-fifty-three subjects visiting the Cardiology Department (Sixth People's Hospital
affiliated to Shanghai JiaoTong University) were examined by coronary arteriography (to diagnose coronary artery
disease (CAD)) and hepatic ultrasonography (to diagnose non-alcoholic fatty liver disease (NAFLD)). Serum FGF21
level was measured by enzyme-linked immunosorbent assay and analyzed for correlation to subject and clinical
characteristics. The independent factors of CAD were determined by multivariate logistic regression analysis.
Results: Subjects with NAFLD showed significantly higher serum FGF21 than those without NAFLD (388.0 pg/mL
(253.0-655.4) vs. 273.3 pg/mL (164.9-383.7), P < 0.01). Subjects with CAD showed significantly higher serum FGF21,
regardless of NAFLD diagnosis (P < 0.05). Serum FGF21 level significantly elevated with the increasing number of
metabolic disorders (P for trend < 0.01). After adjustment of age, sex, and BMI, FGF21 was positively correlated with
total cholesterol (P < 0.05) and triglyceride (P < 0.01). FGF21 was identified as an independent factor of CAD (odds
ratio = 2.984, 95% confidence interval: 1.014-8.786, P < 0.05).
Conclusions: Increased level of serum FGF21 is associated with NAFLD, metabolic disorders and CAD.
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Metabolic syndromeIntroduction
The circulating hormone-like fibroblast growth factor
(FGF) 21 is primarily synthesized by the liver (and to a
lesser extent by the skeletal muscle and pancreas), but
plays an important systemic role in regulating glucolipid
metabolism and insulin sensitivity [1, 2]. The mechanism
of FGF21 activity includes stimulation of glucose trans-
porter protein-1 (GLUT-1) expression to promote glu-
cose uptake and metabolism by fat cells and long-term* Correspondence: byq522@163.com
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reproduction in any medium, provided the orenergy storage [3]. In addition, FGF21 inhibits hepatic
glycogen degradation, thereby reducing levels of circulat-
ing glugagon and helping to maintain the tight hormonal
balance required for proper physiology [4]. All of these
FGF21-mediated effects culminate in a reduction of blood
glucose levels and maintenance of the non-diabetic state.
A key feature of diabetes is perturbed lipid metabolism,
and FGF21 has been implicated in this systemic physio-
logical response as well. Specifically, intravenous injection
of FGF21 in rats was shown to cause marked decreases in
serum levels of triglyceride (TG), free fatty acid, and total
cholesterol (TC) [5]. Large epidemiological studies of hu-
man populations have shown that significantly enhanced
levels of FGF21 accompany obesity, impaired glucosed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease (NAFLD) [2, 6, 7].
Perturbed glucolipid metabolism, and the metabolic
syndrome-NAFLD combination are well known risk fac-
tors for coronary artery disease (CAD) [8]. The associa-
tions of FGF21 and these important risk factors of CAD
prompted our current investigation of whether a direct
relationship exists between serum FGF21 levels and CAD




Subjects visiting the Cardiology Department of the
Sixth People's Hospital Affiliated to Shanghai Jiao Tong
University (China) for examination by coronary arteriog-
raphy were recruited for this study between July 2008 and
January 2010. Study enrollment was denied according
to the presence of acute or chronic viral hepatitis, drug-
induced or alcoholic liver diseases, alcoholism (a total
of ≥ 140 g per week by a male adult or a total of ≥ 70 g
per week by a female [9]), total parenteral nutrition,
chronic kidney diseases, hyper- or hypothyroidism, cancer,
and current treatment with systemic corticosteroids; fur-
thermore, subjects with incomplete anthropometric or la-
boratory data were excluded from analysis.
The study was carried out with pre-approval from the
local Ethics Committee of the Sixth People's Hospital,
and all enrolled subjects provided informed consent.
Physical examination and laboratory testing
The body mass index (BMI) was calculated as weight (in
kilograms) divided by squared-height (in meters). Blood
pressure (BP) was measured by a sphygmomanometer.
Waist circumference (WC) was measured by around the
abdomen, starting horizontally at the midpoint of the cos-
tal margin and following the iliac crest on the mid-axillary
line. Fasting plasma glucose (FPG; measured after a 10 h
overnight fast) and 2 h-postprandial plasma glucose
(2hPG) were assessed by the glucose oxidase method.
Glycated hemoglobin A1c (HbA1c) was detected by high-
pressure liquid chromatography (Variant II; Bio-Rad,
Hercules, CA, USA). Serum lipid profiles including TG,
TC, low-density lipoprotein cholesterol (LDL-c) and
high-density lipoprotein cholesterol (HDL-c) were detected
via standard enzymatic procedures on the 7600–020
autoanalyzer (Hitachi, Tokyo, Japan). Serum C-reactive
protein (CRP) was measured by particle-enhanced
immunonephelometry assay (Dade Behring Inc., Newark,
NJ, USA). Fasting serum insulin was assayed by radio-
immunoassay (Linco Research, St. Charles, MO, USA)
and used to calculate the Homeostasis Model of As-
sessment - Insulin Resistance (HOMA-IR) as follows:
[FPG (mmol/L) × fasting serum insulin (mU/L)] / 22.5.Serum FGF21 was detected by enzyme-linked immuno-
sorbent assay (Antibody and Immunoassay Services,
University of Hong Kong), which gave inter-batch and
intra-batch variances of 7.8% and 9.1%, respectively.
Coronary arteriography and CAD diagnosis
The coronary arteriography was carried out using stand-
ard Judkins technique [10], and all major coronary arteries
were examined in at least two orthogonal views. The arte-
riographic analysis was conducted by two experienced
interventional cardiologists, who were blinded to the
study’s objective and design. CAD was diagnosed when
stenosis was detected in ≥50% of the lumen diameter of a
major coronary artery, including the left main coronary
artery, left anterior descending artery or its first diagonal
branch, left circumflex artery or its first obtuse marginal
branch, and right coronary artery.
Diagnostic criteria for metabolic disorders and NAFLD
Metabolic syndrome (MS) and its components were de-
fined according to the 2007 Joint Committee for Develop-
ing Chinese Guidelines (JCDCG2007) [11], by presence
of ≥ 3 of the following risk factors: abdominal obesity (de-
fined as WC> 90 cm for men and > 85 cm for women);
serum TG level ≥ 1.7 mmol/L or specific treatment for
lipid abnormality; serum HDL-c level < 1.04 mmol/L
or specific treatment for lipid abnormality; BP ≥ 130/
85 mmHg or treatment of previously diagnosed hyperten-
sion; FPG of ≥ 6.1 mmol/L and/or 2hPG of ≥ 7.8 mmol/L
or previously diagnosed type 2 diabetes. Dyslipidemia was
defined as the margin rising of serum lipid level according
to the JCDCG defintion, including serum TC level ≥
5.18 mmol/L; serum TG level ≥ 1.7 mmol/L; serum LDL-c
level ≥ 3.37 mmol/L; serum HDL-c level < 1.04 mmol/L; or
specific treatment for dyslipidemia [11]. NAFLD was diag-
nosed by B ultrasonography. Hepatic steatosis was defined
by a diffuse increase of fine echoes in the liver parenchyma
compared with that in the kidney or spleen parenchyma,
according to the 2010 Prevention and Treatment Guide-
lines for NAFLD published by the Society of Hepatology,
Chinese Medical Association [9]. Smoking status was de-
fined as at least one cigarette per day the past six months
or more [12].
Statistical analysis
The SPSS software suite, version 19.0, was used for all
statistical analyses. Normally distributed data were
expressed as mean ± standard deviation, and skewed data
were expressed as median (inter-quartile range). Inter-
group comparisons of clinical values were carried out by
the unpaired student’s t test (normally distributed data)
or the Mann–Whitney U test (skewed data). Inter-group
comparisons of categorical variables were carried out by
the chi-square test. Partial correlation analysis was
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and clinical parameters. Multivariate logistic regression
analysis was performed to identify the independent fac-
tors of CAD occurrence. All P-values were two-tailed
and considered statistically significant at < 0.05.
Results
Subject characteristics
The study was composed of 253 subjects, represented by
164 men and 89 women, between the ages of 38 and
86 years-old (mean age: 66.3 ± 10.1). All women were
postmenopausal. Serum FGF21 level of men and
women was 291.7 pg/ml (194.0-411.8) and 319.2 pg/ml
(198.3-568.8) respectively with a non-significant resultTable 1 Subject characteristics
Without NAFLD
Variables Total Non-CAD
N = 183 N = 47
Sex(Male/Female) 121/62 23/24
Age, years 67.2 ± 10.0 64.6 ± 9.9
Body mass index, kg/m2 23.9 ± 3.1 24.0 ± 3.5
Waist circumference, cm 88.4 ± 9.3 86.7 ± 9.8
Systolic blood pressure, mmHg 130.0 130.0
(120.0-148.0) (119.0-150.0)
Diastolic blood pressure, mmHg 80.0 80.0
(70.0-80.0) (70.0-85.0)
Fasting plasma glucose, mmol/L 5.3(4.9-6.1) 5.3(5.0-5.9)
2 h postprandial glucose, mmol/L 7.9(6.4-10.7) 7.5(6.1-9.3)
HbA1c,% 6.1(5.7-6.5) 5.9(5.6-6.3)
HOMA-IR 3.8(2.4-5.3) 3.7(2.4-5.4)
Total cholesterol, mmol/L 4.3 ± 1.0 4.6 ± 1.1
Triglyceride, mmol/L 1.4(1.0-1.9) 1.4(0.9-2.0)
HDL-c, mmol/L 1.1 ± 0.3 1.2 ± 0.3
LDL-c, mmol/L 2.9 ± 1.0 3.0 ± 0.9
C-reactive protein, mg/L 1.2(0.5-3.1) 1.0(0.4-3.0)
FGF21, pg/mL 273.3 256.1
(164.9-383.7) (150.6-351.9)
Smoker n (%) 82(44.8) 16(34.0)
Metabolic syndrome and its components
Abdominal obesity n (%) 93(50.8) 22(46.8)
Hypertriglyceridemia n (%) 87(47.5) 20(42.6)
Low HDL-c n (%) 73(39.9) 15(31.9)
Hypertension n (%) 160(87.4) 41(87.2)
Hyperglycemia n (%) 105(57.4) 25(53.2)
Metabolic syndrome n (%) 105(57.4) 24(51.1)
Dyslipidemia n (%) 142(77.6) 34(72.3)
Data were expressed as mean ± SD or median (interquartile range). For both the no
non-CAD. For the total subjects with and without NAFLD: # P < 0.05 NAFLD vs. non-of comparison (P = 0.317). Abdominal ultrasonography
diagnosed 183 of the subjects without NAFLD. Subjects
with NAFLD showed a significantly higher level of serum
FGF21 (388.0 pg/mL (253.0-655.4) vs. those without
NAFLD: 273.3 pg/mL (164.9-383.7), P < 0.01).
The NAFLD and non-NAFLD groups were further
divided into two subgroups according to the presence of
CAD judged by the coronary arteriography. As shown in
Table 1, among subjects without NAFLD, those with
CAD showed significantly higher age, 2hPG, and signifi-
cantly lower HDL-c and TC (vs. subjects without CAD, all
P < 0.05). While among subjects with NAFLD, those with
CAD and without CAD showed significant differences also
in serum TG besides serum FGF21 (P < 0.05). ConcerningWith NAFLD
CAD Total Non-CAD CAD
N = 136 N = 70 N = 27 N = 43
98/38 43/27 16/11 27/16
68.2 ± 9.9* 63.9 ± 9.9# 61.3 ± 7.7 65.5 ± 10.9
23.9 ± 2.9 26.5 ± 3.7## 26.5 ± 4.9 26.5 ± 2.8
88.9 ± 9.0 95.4 ± 9.3## 96.6 ± 11.7 94.7 ± 7.6
130.0 140.0 140.0 140.0
(120.0-147.8) (128.8-151.5)# (120.0-150.0) (130.0-153.0)
80.0 80.0 80.0 80.0
(70.0-80.0) (71.8-90.0)## (70.0-85.0) (72.0-90.0)
5.3(4.9-6.1) 5.8(5.2-7.2)## 5.6(5.1-6.6) 5.9(5.4-7.7)
8.0(6.5-11.5)* 10.4(8.2-12.9)## 9.7(7.9-12.9) 11.3(8.2-12.9)
6.2(5.8-6.6) 6.5(5.9-7.6)## 6.3(5.7-7.1) 6.6(6.2-7.9)
3.9(2.4-5.3) 6.0(3.7-7.2)## 5.9(3.7-6.4) 6.6(3.7-9.2)
4.2 ± 1.0* 4.7 ± 1.3# 4.5 ± 1.4 4.8 ± 1.2
1.4(1.0-1.8) 2.2(1.4-3.1)## 1.7(1.3-2.4) 2.6(1.6-3.7)*
1.1 ± 0.3* 1.0 ± 0.3## 1.0 ± 0.3 1.0 ± 0.3
2.9 ± 1.0 3.1 ± 1.0 3.1 ± 1.0 3.2 ± 1.0
1.2(0.5-3.3) 2.3(1.0-6.9)## 1.6(0.7-6.3) 2.5(1.1-7.6)
277.8 388.0 321.5 415.5
(171.1-406.6)* (253.0-655.4)## (239.1-497.6) (258.0-693.7)*
66(48.5) 31(44.3) 12(44.4) 19(44.2)
71(52.2) 55(78.6)## 21(77.8) 34(79.1)
67(49.3) 50(71.4)## 14(51.9) 36(83.7)**
58(42.6) 41(58.6)# 14(51.9) 27(62.8)
119(87.5) 63(90.0) 23(85.2) 40(93.0)
80(58.8) 56(80.0)## 21(77.8) 35(81.4)
81(59.6) 63(90.0)## 23(85.2) 40(93.0)
108(79.4) 68(97.1)## 25(92.6) 43(100.0)
n-NAFLD and NAFLD groups: * P < 0.05 CAD vs. non-CAD; ** P < 0.01 CAD vs.
NAFLD; ## P < 0.01 NAFLD vs. non-NAFLD.
Figure 2 Differential serum FGF21 level among subjects with
various components of MS. P < 0.01 for trend of elevated serum
FGF21 level with increasing number of disorders.
Table 2 Partial correlation analysis between FGF21 and
clinical variables
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glyceridemia was higher in CAD subjects with NAFLD
(vs. non-CAD subjects with NAFLD, P < 0.01).
As seen in Figure 1, both subjects with and without
CAD showed a significant elevation of serum FGF21
level in the NAFLD group compared to the non-NAFLD
group (415.5 pg/mL (258.0-693.7) vs. 277.8 pg/mL (171.1-
406.6), P < 0.01; 321.5 pg/mL (239.1-497.6) vs. 256.1 pg/mL
(150.6-351.9), P < 0.05). Similarly in subjects with and
without NAFLD, serum FGF21 level was elevated in the
CAD subgroup compared to the non-CAD subgroup
(415.5 pg/mL (258.0-693.7) vs. 321.5 pg/mL (239.1-497.6),
P < 0.05; 277.8 pg/mL (171.1-406.6) vs. 256.1 pg/mL
(150.6-351.9), P < 0.05).
Association of serum FGF21 level with MS and -related
clinical parameters
When the subjects were grouped according to MS status
and divided into subgroups according to the particular
components of MS, a trend in increasing serum FGF21
level accompanying increased numbers of MS-related
disorders was noticed (P for trend < 0.01; Figure 2). After
adjustment of age, sex and BMI, correlation analysis
showed that a significant positive relationship existed be-
tween FGF21 and TC (P < 0.05), as well as TG (P < 0.01;
Table 2).
Association between serum FGF21 level and CAD
Multivariate logistic regression analysis was structured with
independent variables of age, sex, BMI, WC, HOMA-IR,
FGF21, smoking status, hyperglycemia, family history of
CAD, hypertension, NAFLD, and dyslipidemia (Table 3).
Consequently, male subjects were found more prone to
CAD (P < 0.01). In addition, serum FGF21 level was iden-
tified as one of the independent factors of CAD, along
with age. The odds ratio of FGF21 was 2.984 with a 95%
confidence interval of 1.014-8.786 (P < 0.05).Figure 1 Differential serum FGF21 level among subjects with
NAFLD and/or CAD. White bars, total; grey bars, non-CAD
subgroup; black bars, CAD subgroup. * P < 0.05, CAD subgroup vs.
non-CAD subgroup; # P < 0.05, ## P < 0.01, NAFLD group vs. non-
NAFLD group.Discussion
The contribution of metabolic disorders to development
and progression of cardiovascular diseases has been exten-
sively studied. In recent years, however, the important role
of cytokines, and resultant inflammation, in this etiological
relationship has been recognized. Mainly characterized as
a metabolic factor, the newly-recognized cytokine charac-
teristics of FGF21 have stimulated research interest in its
putative roles in the inflammation-related processes of
metabolic disorders and diseases. The collective evidence,
however, has revealed a more complex role for this factor
in normal metabolic processes and pathogeneses. For ex-
ample, animal studies have demonstrated that FGF21 pro-
motes glycolipid metabolism and insulin sensitivity but
clinical studies of humans have yielded opposite results
[13, 14]. Mraz M, et al. reported that serum FGF21 level
becomes elevated under conditions of insulin resistance
[15], and An et al. showed that increased serum FGF21Partial correlation
Variables R P
Waist circumference 0.102 0.129
Systolic blood pressure 0.100 0.136
Diastolic blood pressure 0.040 0.548
Fasting plasma glucose 0.077 0.248
2 h postprandial glucose 0.056 0.405
HbA1c 0.027 0.684
HOMA-IR 0.080 0.233
Total cholesterol 0.154 0.021
Triglyceride 0.317 <0.001
High-density lipoprotein cholesterol −0.095 0.157
Low-density lipoprotein cholesterol 0.077 0.248
C-reactive protein 0.068 0.314
Partial correlation was made after adjustment for age, sex, and BMI.
Table 3 Independent factors of CAD identified by
multivariate logistic regression analysis
β S.E OR P
Sex −0.882 0.304 0.414(0.228-0.752) 0.004
FGF21a 1.093 0.551 2.984(1.014-8.786) 0.047
Age 0.043 0.015 1.044(1.013-1.076) 0.005
Variables included in the model were age, sex, BMI, WC, HOMA-IR, FGF21,
smoking status, hyperglycemia, family history of CAD, hypertension, NAFLD,
and dyslipidemia.
aData were after logarithm.
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plaques in patients with type 2 diabetes [16].
Studies of the relationship of enhanced FGF21 levels
with NAFLD have provided slightly more consistent evi-
dence. Cross-sectional clinical studies have demonstrated
an incremental increase in FGF21 levels with increased
severity of NAFLD [2]; in particular increased mRNA
expression of FGF21 has been shown in hepatic biopsies
[6]. Furthermore, a 3-year follow-up of NAFLD subject
outcome indicated that serum FGF21 level might be a
clinically-relevant disease biomarker, suggesting its poten-
tial for monitoring response to therapy [17]. In the present
study, NAFLD subjects were found to have higher level of
serum FGF21 and those subjects with multiple metabolic
disorders were found to have the highest level of serum
FGF21, thereby supporting the hypothesis that this factor
is involved in glycolipid metabolism.
The etiological process leading from NAFLD to ath-
erosclerosis is believed to involve a cluster of metabolic
disorders and other co-morbidities (possibly inflammation-
related). The most dangerous atherosclerosis manifestation
is coronary atherosclerotic heart disease and research ef-
forts have focused on defining the relationship between
metabolic-related and inflammation-related serum factors
(such as FGF21) and CAD. In a recent study to determine
the clinical profile of CAD, using findings from electrocar-
diogram, serology and physical symptoms (such as chest
discomfort), it was found that elevated serum FGF21 level
was a distinctive marker [18]; this observation also served
to indicate that FGF21 might be involved in the patho-
physiological process of CAD. Lee et al. studied the rela-
tion between serum FGF21 and CAD diagnosis according
to computed tomography findings and found that serum
FGF21 level was significantly correlated with serum TG,
LDL-c, HOMA-IR and the occurrence of MS; however, no
relationship was found between serum FGF21 level and
CAD diagnosed by computed tomography [19]. Both of
these studies of the clinical features of CAD relied on in-
patient populations with a high risk of various metabolic
disorders, but ignored the possible influence of NAFLD.
In the current study of the relationship between FGF21
and CAD, subjects undergoing coronary arteriography
were analyzed. A significant elevation of serum FGF21among CAD subjects was discovered independently of
NAFLD status. Multivariate logistic regression analysis
also identified serum FGF21 level as one of the independ-
ent factors of CAD occurrence.
Enhanced serum FGF21 level has been previously
demonstrated in subjects with obesity, diabetes, and
dyslipidemia. Moreover, the enhanced serum FGF21
level has been correlated to presence of insulin resist-
ance, and increased levels of TC and TG. For example,
Cheng et al. identified FGF21 as a predictive marker of
diabetes, but also showed that the elevated level did not
correlate with disease duration [20]. Similarly, Li et al.
reported significantly increased level of FGF21 in indi-
viduals with impaired glucose tolerance, and showed a
significant positive relationship of FGF21 level with TC
and TG level [21]. The findings of the current study
presented herein agree with these data, collectively
supporting the hypothesis that serum FGF21 level is
likely involved in the process of CAD; the current study
provides novel insights into the contribution of FGF21
being independent of such traditional cardiac risk factors
as age, hyperglycemia, hypertension, dyslipidemia, and
even NAFLD.
Insulin resistance is a main pathophysiological foun-
dation of NAFLD, along with type 2 diabetes and even
MS and cardiovascular diseases. Serum FGF21 level has
been found to be higher in insulin resistance status in
both human-based studies and rat experiments [22]. In
addition, Shargorodsky M, et al. found that subjects
with significant improvement of insulin resistance also
tended to show significant improvement on central aortic
augmentation index. This result suggested that insulin re-
sistance might be involved in the process of arterial lesions
[23]. A Japanese study even recommended using ALT/
AST ratio to reflect the extent of insulin resistance [24].
Therefore, FGF21, a mainly liver-derived cytokine, was
found to be associated with the occurrence of CAD in this
study, which might be explained, concerning the mechan-
ism, by the involvement of insulin resistance.
Individuals with a cluster of metabolic disorders have
increased serum FGF21 level, and research has impli-
cated the up-regulation of this cytokine as acting to
compensate for the abnormal metabolic status [25]. This
compensatory mechanism may explain the apparent in-
consistent findings from animal and human studies of
FGF21 and metabolic disorders. Elevated mRNA expres-
sion of FGF21 was found in rat cardiac micro-vascular
endothelial cells (CMECs) cultured in atherosclerosis-like
conditions [26]; furthermore, exogenous FGF21 infusion
to the CMEC atherosclerosis-promoting culture signifi-
cantly inhibited the cells’ apoptosis. These findings sug-
gested that up-regulated FGF21 expression might be
protective at the early stage of atherosclerosis, helping the
cells to recover normal endothelial function. Thus, it is
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subjects of our study represent a similar compensatory
mechanism, by which the system is attempting to protect
against atherosclerosis. While this study is the first to
provide clinical evidence of the relationship between
serum FGF21 level and CAD diagnosed by coronary ar-
teriography, further animal studies should be conducted
to reveal the exact mechanism between FGF21 and
atherosclerosis.
Limitations
Some inherent features of the current study’s design may
have affected the results and may limit generalization of
the findings. First, the sample size was relatively small
for the cross-sectional study design and some inherent
bias may have been masked. Second, the study population
was relatively homogenous, characterized by Chinese
adults, middle- and old-aged, presenting at a single health
institute and focused clinical care department (cardiology);
generally, these subjects represent a high-risk of CAD.
Conclusions
In a study of subjects undergoing coronary angiography,
serum FGF21 level was significantly higher among the
individuals with NAFLD. Moreover, the elevated serum
FGF21 level followed a positive incremental trend in
conjunction with amount of metabolic disorders present
in the patient. Finally, subjects with CAD had higher
serum FGF21 level than those without CAD, regardless
of NAFLD status, and FGF21 was identified as an inde-
pendent factor of CAD. Considering these results in
conjunction with the collective findings from previous
related clinical studies, serum FGF21 elevation may rep-
resent a regulatory compensation mechanism under ath-
erosclerosis conditions, and may represent a promising
therapeutic target for this disease.
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